Realistic pathologic classification of acute myeloid leukemias

American Journal of Clinical Pathology

Volumn 115, Issue 4, 2001, Pages 552-560

  Arber, Daniel A ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Acute myeloid leukemia; Classification; Cytogenetics; French American British classification; Immunophenotyping; World Health Organization

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MEGAKARYOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CYTOGENETICS; DISEASE CLASSIFICATION; GENE TRANSLOCATION; HISTOPATHOLOGY; IMMUNOPHENOTYPING; MOLECULAR GENETICS; MYELODYSPLASIA; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION;

ACUTE DISEASE; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, PAIR 15; HUMANS; IMMUNOPHENOTYPING; KARYOTYPING; LEUKEMIA, MEGAKARYOCYTIC, ACUTE; LEUKEMIA, MYELOID; LEUKEMIA, PROMYELOCYTIC, ACUTE; WORLD HEALTH ORGANIZATION;

EID: 0035060568     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/K2PH-L2U7-722B-B1YR     Document Type: Article

References (65)

1. Bennett JM, Catovsky D, Daniel M-T, et al. Proposals for the classification of the acute leukemias. Br J Haematol. 1976;33:451-458.
2. Bennett JM, Catovsky D, Daniel M-T, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:626-629.
3. Bennett JM, Catovsky D, Daniel M-T, et al. Criteria for the diagnosis of acute leukemia of megakaryocytic lineage (M7): a report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:460-462.
4. Bennett JM, Catovsky D, Daniel M-T, et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0). Br J Haematol. 1991;78:325-329.
5. Bennett JM, Cassileth PA, Paietta E, et al. Morphologic classification of acute myeloid leukemia: concordance among Eastern Cooperative Oncology Group investigators: a comment. Leukemia. 1996;10:1365.
6. Second MIC Cooperative Study Group. Morphologic, immunologic, and cytogenetic (MIC) working classification of the acute myeloid leukemias: report of the workshop held in Leuven, Belgium, September 15-17, 1986. Cancer Genet Cytogenet. 1988;30:1-15.
7. Bene MC, Castoldi G, Knapp W, et al. Proposal for the immunologic classification of acute leukemias. Leukemia. 1995;9:1783-1786.
8. Head DR. Revised classification of acute myeloid leukemia. Leukemia. 1996;10:1826-1831.
9. Kita K, Nakase K, Miwa H, et al. Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood. 1992;80:470-477.
10. Larson RA, Williams SF, Le Beau MM, et al. Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favorable prognosis. Blood. 1986;68:1242-1249.
11. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting: Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849.
12. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322-2333.
13. Gahn B, Haase D, Unterhalt M, et al. De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance. Leukemia. 1996;10:946-951.
14. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
15. Fenaux P, Preudhomme C, Lai JL, et al. Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: report on 283 cases. Br J Haematol. 1989;73:61-67.
16. Dastugue N, Payen C, Lafage-Pochitaloff M, et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. Leukemia. 1995;9:1491-1498.
17. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58:4173-4179.
18. Estey E, Thall P, Beran M, et al. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood. 1997;90:2969-2977.
19. Khalidi HS, Medeiros LJ, Chang KL, et al. The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities. Am J Clin Pathol. 1998;109:211-220.
20. Nakamura H, Kuriyama K, Sadamori N, et al. Morphological subtyping of acute myeloid leukemia with maturation (AML-M2): homogeneous pink-colored cytoplasm of mature neutrophils is most characteristic of AML-M2 with t(8;21). Leukemia. 1997;11:651-655.
21. Hurwitz CA, Raimondi SC, Head D, et al. Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. Blood. 1992;80:3182-3188.
22. Arber DA, Glackin C, Lowe G, et al. Presence of t(8;21)(q22;q22) in myeloperoxidase-positive, myeloid surface antigen-negative acute myeloid leukemia. Am J Clin Pathol. 1997;107:68-73.
23. Baer MR, Stewart CC, Lawrence D, et al. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood. 1997;90:1643-1648.
24. Schoch C, Haase D, Haferlach T, et al. Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor. Leukemia. 1996;10:1288-1295.
25. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337:1021-1028.
26. Lo Coco F, Nervi C, Avvisati G, et al. Review and meeting report: acute promyelocytic leukemia: a curable disease. Leukemia. 1998;12:1866-1880.
27. Guglielmi C, Martelli MP, Diverio D, et al. Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome: a cooperative Italian study on 196 cases. Br J Haematol. 1998;102:1035-1041.
28. Neame PB, Soamboonsrup P, Leber B, et al. Morphology of acute promyelocytic leukemia with cytogenetic or molecular evidence for the diagnosis: characterization of additional microgranular variants. Am J Hematol. 1997;6:131-142.
29. Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood. 1999;93:3167-3215.
30. Grimwade D. The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease. Br J Haematol. 1999;106:591-613.
31. Sainty D, Liso V, Cantù-Rajnoldi A, et al. A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements. Blood. 2000;96:1287-1296.
32. LeBeau MM, Larson RA, Bitter MA, et al. Association of an inversion of chromosome 16 and abnormal marrow eosinophils in acute myelomonocytic leukemia. N Engl J Med. 1983;309:630-636.
33. Liu PP, Hajra A, Wijmenga C, et al. Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia. Blood. 1995;85:2289-2302.
34. Adriaansen HJ, te Boekhorst PAW, Hagemeijer AM, et al. Acute myeloid leukemia M4 with bone marrow eosinophilia (M4Eo) and inv(16)(p13q22) exhibits a specific immunophenotype with CD2 expression. Blood. 1993;81:3043-3051.
35. Paietta E, Wiernik PH, Andersen J, et al. Acute myeloid leukemia M4 with inv(16) (p13q22) exhibits a specific immunophenotype with CD2 expression [letter]. Blood. 1993;82:2595.
36. Ribeiro RC, Oliveira MSP, Dairclough D, et al. Acute megakaryoblastic leukemia in children and adolescents: a retrospective analysis of 24 cases. Leuk Lymphoma. 1993;10:299-306.
37. Gassmann W, Löffler H. Acute megakaryoblastic leukemia. Leuk Lymphoma. 1995;18(suppl 1):69-73.
38. Lu G, Altman AJ, Benn PA. Review of the cytogenetic changes in acute megakaryoblastic leukemia: one disease or several? Cancer Genet Cytogenet. 1993;67:81-89.
39. Lion T, Haas OA, Harbott J, et al. The translocation t(1;22)(p13;q13) is a nonrandom marker specifically associated with acute megakaryocytic leukemia in young children. Blood. 1992;79:3325-3330.
40. Chan WC, Carroll A, Alvarado CS, et al. Acute megakaryoblastic leukemia in infants with t(1;22)(p13;q13) abnormality. Am J Clin Pathol. 1992;98:214-221.
41. Bernstein J, Dastugue N, Haas OA, et al. Nineteen cases of the t(1;22)(p13;q13) acute megakaryoblastic leukaemia of infants/children and a review of 39 cases: report from a t(1;22) study group. Leukemia. 2000;14:216-218.
42. Goasguen JE, Matsuo T, Cox C, et al. Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: major importance of dysgranulopoiesis for remission and survival. Leukemia. 1992;6:520-525.
43. Pui C-H, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med. 1991;325:1682-1687.
44. Pedersen-Bjergaard J, Rowley JD. The balanced and unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood. 1994;83:2780-2786.
45. Andersen MK, Pedersen-Bjergaard J. Increased frequency of dicentric chromosomes in therapy-related MDS and AML compared to de novo disease is significantly related to previous treatment with alkylating agents and suggests a specific susceptibility to chromosome breakage at the centromere. Leukemia. 2000;14:105-111.
46. Micallef INM, Lillington DM, Apostolidis J, et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol. 2000;18:947-955.
47. Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood. 2000;95:1588-1593.
48. Raimondi SC, Chang MN, Ravindranath Y, et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative Pediatric Oncology Group study: POG 8821. Blood. 1999;94:3707-3716.
49. Li Y-S, Zhao Y-L, Jiang Q-P, et al. Specific chromosome changes and nonoccupational exposure to potentially carcinogenic agents in acute leukemia in China. Leuk Res. 1989;13:367-376.
50. Xue Y, Lu D, Guo Y, et al. Specific chromosomal translocations and therapy-related leukemia induced by bimolane therapy for psoriasis. Leuk Res. 1992;16:1113-1123.
51. Kudo K, Yoshida H, Kiyoi H, et al. Etoposide-related acute promyelocytic leukemia. Leukemia. 1998;12:1171-1175.
52. Roulston D, Espinosa IR, Nucifora G, et al. CBFA2 (AML1) translocations with novel partner chromosomes in myeloid leukemias: association with prior therapy. Blood. 1998;92:2879-2885.
53. Garand R, Duchayne E, Blanchard D, et al. Minimally differentiated erythroleukaemia (AML M6 "variant"): a rare subset of AML distinct from AML M6. Br J Haematol. 1995;90:868-875.
54. Davey FR, Abraham N Jr, Brunetto VL, et al. Morphologic characteristics of erythroleukemia (acute myeloid leukemia; FAB-M6): a CALGB study. Am J Hematol. 1995;49:29-38.
55. Wick MR, Li C-Y, Pierre RV. Acute nonlymphocytic leukemia with basophilic differentiation. Blood. 1982;60:38-45.
56. Peterson LC, Parkin JL, Arthur DC, et al. Acute basophilic leukemia: a clinical, morphologic, and cytogenetic study of eight cases. Am J Clin Pathol. 1991;96:160-170.
57. Taylor CG, Stasi R, Bastianelli C, et al. Diagnosis and classification of the acute leukemias: recent advances and controversial issues. Hematopathol Mol Hematol. 1996;10:1-38.
58. Alsabeh R, Brynes RK, Slovak ML, et al. Acute myeloid leukemia with t(6;9) (p23;q34): association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype. Am J Clin Pathol. 1997;107:430-437.
59. Paietta E, Recevskis J, Bennett JM, et al. Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: the Eastern Cooperative Oncology Group experience. Leukemia. 1998;12:1881-1885.
60. Bearman RM, Pangalis GA, Rappaport H. Acute ("malignant") myelosclerosis. Cancer. 1979;43:279-293.
61. Den Ottolander GJ, te Velde J, Brederoo P, et al. Megakaryoblastic leukaemia (acute myelofibrosis): a report of three cases. Br J Haematol. 1979;42:9-20.
62. Bain BJ, Catovsky D, O'Brien M, et al. Megakaryoblastic leukemia presenting as acute myelofibrosis: a study of four cases with the platelet-peroxidase reaction. Blood. 1981;58:206-213.
63. Schreeder MT, Prchal JT, Parmley RT, et al. An acute myeloproliferative disorder characterized by myelofibrosis and blast cells that express phenotypic properties associated with multiple hematopoietic lineages. Am J Clin Pathol. 1985;83:114-121.
64. Hruban RH, Kuhajda FP, Mann RB. Acute myelofibrosis: immunohistochemical study of four cases and comparison with acute megakaryocytic leukemia. Am J Clin Pathol. 1987;88:578-588.
65. European Group for the Immunological Classification of Leukaemias. The value of c-kit in the diagnosis of biphenotypic acute leukemia [letter]. Leukemia. 1998;12:2038.